Pinterest • The world’s catalog of ideas

Marriott International Stock #tradestocks, tradingcfds, stockprices, marstock, stockcharts

2
from Reuters India

AstraZeneca gets up to $500 million from Lilly for Alzheimer's drug

AstraZeneca to partner with Eli Lilly on Alzheimer's drug | Reuters

Eli Lilly’s revenue has actually declined over the past five years, in large part due to expiring patents. Operating profit has shrunk from $6.5 billion all the way down to $2.3 billion. Meanwhile, Eli Lilly’s profit margin has been cut nearly in half. It’ll be very challenging to return margins to their prior levels for a variety of reasons. For example, the patent on Cialis, a high-margin erectile dysfunction drug, expires in 2017.

Company Update: Eli Lilly & Company (NYSE:LLY) – Lilly and Sanford-Burnham Announce Collaboration to Investigate Immunological Therapies By Heather Cunnings, on May 14th, 2015

1

“Eli Lilly and the pharmaceutical industry were the only winners benefiting from $101.2 million of public funds and the public is not allowe...

1

Point Roberts WA, New York, NY - February 19, 2014 (Investorideas.com Biotech Newswire) Investorideas.com global news source covering leading sectors including biotech and pharma reports on companies in the sector targeting pancreatic cancer. Stocks mentioned include NewLink Genetics (NLNK), Sunshine Biopharma Inc. ( OTCBB: SBFM ), Eli Lilly and Company (NYSE:LLY) and Celgene (NASDAQ:CELG).